Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued on Wednesday, Marketbeat reports. The brokerage presently has a $15.00 price target on the stock, up from their previous price target of $12.00. Raymond James’ price target indicates […]
Fusion Pharmaceuticals (NASDAQ:FUSN) Coverage Initiated by Analysts at Royal Bank of Canada etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Sees Significant Decrease in Short Interest kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Expected to Post Q4 2023 Earnings of ($0.36) Per Share theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cano Health, Inc. (NYSE:CANO – Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 30,520,000 shares, a decrease of 7.0% from the September 15th total of 32,800,000 shares. Currently, 14.3% of the company’s stock are sold short. Based on an average daily trading […]